Ulcerative Colitis


ICER will assess the comparative clinical effectiveness and value of therapies for ulcerative colitis (UC), including:

  • Vedolizumab (Entyvio®, Takeda)
  • Infliximab (Remicade®, Janssen)
  • Infliximab-dyyb (Inflectra®, Pfizer)
  • Infliximab-abda (Renflexis®, Merck)
  • Adalimumab (Humira®, AbbVie)
  • Golimumab (Simponi®, Janssen)
  • Tofacitinib (Xeljanz®, Pfizer)
  • Ustekinumab (Stelara®, Janssen)

Date of Review: September 2020

For questions, please contact Laura Cianciolo, Program Manager, at lcianciolo@icer-review.org.

Associated Meetings

September 24, 2020 9:30am-2:30pm PT

The CTAF will convene virtually to deliberate and vote on evidence presented in ICER's report on ulcerative colitis therapies.

Key Dates

Associated Materials